A phase I trial was conducted to evaluate the effects of low, medium, and high doses of DEN-181 on autoreactive T-cell responses, cytokines, and ACPA in RA patients on methotrexate [23]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.